Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease (ESRD)
Primary Purpose
End Stage Renal Disease
Status
Withdrawn
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
low and high dose flavanoids
Sponsored by
About this trial
This is an interventional treatment trial for End Stage Renal Disease
Eligibility Criteria
Inclusion Criteria:
- patients with end stage renal disease
Exclusion Criteria:
- person under 18 years of age
- participation in another study
Sites / Locations
- Düsseldorf University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
1
2
Arm Description
Treatment with low dose flavanoids
Treatment with high dose flavanoids
Outcomes
Primary Outcome Measures
Vascular function
Secondary Outcome Measures
Full Information
NCT ID
NCT00835887
First Posted
February 3, 2009
Last Updated
September 22, 2015
Sponsor
RWTH Aachen University
Collaborators
Heinrich-Heine University, Duesseldorf
1. Study Identification
Unique Protocol Identification Number
NCT00835887
Brief Title
Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease
Acronym
ESRD
Official Title
Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease, a Phase 2 Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2015
Overall Recruitment Status
Withdrawn
Why Stopped
no patients recruited, responsible physician left clinic
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
RWTH Aachen University
Collaborators
Heinrich-Heine University, Duesseldorf
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this study, the acute and long-term effects of flavanols on vascular function in patients with ESRD will be investigated.
Detailed Description
In order to assess potential acute beneficial effects of flavanols in patients with ESRD, 10 patients undergoing dialysis will be recruited. Subjects will receive a cocoa drink with 16 mg, 250 mg, and 500 mg (in 100 mL water each) flavan-3-ols (40% epicatechine/catechine und 60% procyanidine), respectively, on three consecutively days. The functional/hemodynamic parameters (flowmediated dilation (FMD), venous-occlusion-plethysmography (VOP), blood pressure, heart rate), the biochemical marker of the circulating NO pool (nitrite, nitrate, RNOs), and the plasma levels of flavanols (epicatechine and catechine) will be determined before and after ingestion of the respective cocoadrink.
It is expected that flavanols dose-dependently improve vascular function and that this is associated with an increase in the circulating NO pool.
In order to assess long-term effects of flavanols on vascular function in patients with ESRD.
To characterize potential vascular long-term effects of flavanols in patients with ESRD, a placebo-controlled double-blinded randomized control study will be performed in 40 patients randomized in two groups. Patients will daily receive either a flavanol-poor cocoa drink or a flavanol-rich cocoa drink over a period of three months.
The flavanol-dosis that is necessary to affect vascular function will be assessed as described above. At the beginning of the study, after the first intake of the cocoa (in order to identify nonresponders) and monthly for a period of three months the vascular function will be assessed applying innovative imaging techniques to the brachial artery to assess endothelium-dependent regulation of physicomechanical properties and vascular tone and thus blood flow at the level of the macrocirculation. In parallel new techniques will be applied to assess perfusion at the level of the microcirculation. In particular, measurement of flow-mediated dilation, intima-media-thickness,compliance and stiffness indices will be performed in the macrocirculation of the brachial artery.
Considering the microcirculation, new diagnostic approaches such as Laser-Doppler Flow and peripheral arterial tonometry next to diagnostic approaches such as the venous occlusive plethysmography will be performed. Moreover, the circulating NO pool, markers of inflammation and of oxidative stress, the uremic toxin pcresol and the plasma levels of flavanols will be determined. The exams after month 1, 2, and 3 will be performed in the morning before intake of the cocoa drink. In order to examine potential sustained effects, an additional examination day will take place after 4 month (one month after stopping the flavanol-intake). It is expected that the flavanol-rich cocoa will improve vascular function, which is associated with an increase in the circulating NO-pool and a decrease in inflammatory markers and the marker for oxidative stress.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Treatment with low dose flavanoids
Arm Title
2
Arm Type
Experimental
Arm Description
Treatment with high dose flavanoids
Intervention Type
Dietary Supplement
Intervention Name(s)
low and high dose flavanoids
Intervention Description
treatment with flavanoid-rich or flavanoid-low cacao twice daily
Primary Outcome Measure Information:
Title
Vascular function
Time Frame
before treatment, directly after treatment and 3, resp. 4 months afterwards
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with end stage renal disease
Exclusion Criteria:
person under 18 years of age
participation in another study
Facility Information:
Facility Name
Düsseldorf University Hospital
City
Düsseldorf
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease
We'll reach out to this number within 24 hrs